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Background 
Primary hypothyroidism is an insidious condition with a significant morbidity and 
often subtle and non-specific symptoms and clinical signs [1, 2]. The earliest 
biochemical abnormality is an increase in serum thyroid-stimulating hormone 
(thyrotrophin) (TSH) concentration associated with normal serum free thyroxine (T4) 
and triiodothyronine (T3) concentrations (subclinical hypothyroidism), followed by a 
decrease in serum free T4 concentration, at which stage most patients have 
symptoms and benefit from treatment (overt hypothyroidism) [1-3]. In the UK, the 
prevalence of spontaneous hypothyroidism is between 1% and 2%, and it is more 
common in older women and ten times more common in women than in men [4, 5]. 
The cause is either chronic autoimmune disease (atrophic autoimmune thyroiditis or 
goitrous autoimmune thyroiditis (Hashimoto's thyroiditis)) or destructive treatment for 
hyperthyroidism with either radioiodine or surgery which may account for up to one-
third of cases of hypothyroidism in the community [6]. Less frequent causes include 
surgery and radioiodine ablation for benign nodular thyroid disease and thyroid 
cancer, external beam irradiation of malignant tumours of the head and neck and 
drugs including lithium, amiodarone and interferon [1]. Congenital hypothyroidism 
affects about one newborn in 3,500-4,000 births [7]. 
The term subclinical hypothyroidism describes the finding of a raised serum TSH but 
a normal free T4 [3, 8, 9]. It represents a compensated state in which increased TSH 
output is required to maintain normal circulating thyroid hormone levels. An elevated 
serum TSH is a sensitive indicator of some degree of thyroid failure and there is a 
clear inverse relationship with free T4 levels. The term implies that patients should 
be asymptomatic, although symptoms are difficult to assess, especially in patients in 
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whom thyroid function tests have been checked because of non-specific complaints 
such as tiredness. Subclinical hypothyroidism is common in studies of healthy 
people in the community and is found in 5-10% of the population, being more 
common in women and increasing with age [9]. It can progress to overt 
hypothyroidism, particularly if anti-thyroid antibody positive [10]. In the community, 
the most common aetiology is chronic autoimmune thyroiditis [6].  
There has been a growing controversy about the upper limit of the reference range 
for serum TSH [11, 12]. Reference ranges are derived from a reference population 
that comprises a large group of subjects who do not have thyroid disease and are 
otherwise well. By convention, a reference range usually only comprises 95% of a 
reference population. Thus 2.5% of “normal” individuals will fall above the reference 
range and 2.5% will fall below the range. For serum TSH the reference population 
shows a log normal distribution and has a diurnal variation with the reference range 
in thyroid disease free individuals typically cited as between 0.4-4.0 mU/l [8]. The 
reference range varies in different ethnic communities, pregnancy and by age [13]. It 
has been reported that serum TSH distribution progressively shifts towards higher 
concentration with age [13]. Studies addressing the relationship between symptoms 
suggestive of thyroid hormone deficiency and the biochemical finding of subclinical 
hypothyroidism have produced conflicting results [3]. It is recognised that up to one 
quarter of the healthy normal population may have “hypothyroid” symptoms such as 
lethargy and weight gain [14]. The evidence for benefit in randomised controlled 
trials of thyroid hormone treatment in subclinical hypothyroidism is inconsistent and 
further studies are needed [3, 15]. Although epidemiological studies have shown an 
association between subclinical hypothyroidism and coronary heart disease in 
younger people (<65 years) [16] or those with high TSH (>10 mU/L) [17], recent 
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evidence suggests that in older people higher serum TSH and lower free T4 
concentrations within the euthyroid range are associated with lower risk of multiple 
adverse events including mortality [18]. In neonates and children, pregnancy, or in 
women trying to conceive a mildly increased serum TSH should always be treated as 
mild thyroid failure which is associated with adverse outcomes for both mother and 
fetus [19]. 
In England, 3% of people are prescribed synthetic L-T4 [20] with the goal of therapy 
being to restore patient well-being and normalise serum TSH levels [21]. Most 
patients respond satisfactorily but a minority of treated individuals experience 
persistent symptoms despite adequate biochemical correction [22]. The care of such 
individuals is challenging and r mains the subject of considerable public interest 
[23]. Although some non-mainstream practitioners advocate the use of alternative 
thyroid therapies including Liothyronine (L-T3) and thyroid extracts, combination 
therapy with L-T4 and L-T3 is also prescribed by accredited specialists. In the United 
States, 3.6% of endocrinologists report that they would give L-T3 to patients with 
hypothyroidism with persistent symptoms and normal biochemical thyroid status [24]. 
In 2008 the Royal College of Physicians (RCP) issued a position statement on the 
diagnosis and management of primary hypothyroidism endorsed by various 
professional bodies namely the British Thyroid Association (BTA), the British Thyroid 
Foundation (BTF), the Association for Clinical Biochemistry and Laboratory Medicine 
(ACB), the British Society of Paediatric Endocrinology and Diabetes (BSPED), the 
Society for Endocrinology (SFE), and the Royal College of General Practitioners 
(RCGP) [25]. This RCP statement, updated in 2011, did not support the use of 
thyroid extracts or L-T3 in the treatment of hypothyroidism and recommended that L-
Page 4 of 31Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Management of primary hypothyroidism  
5 | P a g e  
 
T3 “should be reserved for use by accredited endocrinologists in individual patients” 
[25].  
More recently, the European Thyroid Association (ETA) published guidelines on the 
use of L-T4/L-T3 combination therapy in primary hypothyroidism [26] and 
subsequently, the American Thyroid Association (ATA) [27] and the Latin America 
Thyroid Society (LATS) [28] have released their own separate hypothyroidism 
treatment guidelines. These international guidelines have generated further interest 
in the role of L-T3 in hypothyroidism and have been interpreted in some quarters as 
representing a departure from the earlier UK RCP position [29].  
It is recognised that clinicians must be committed to delivering individualised patient-
centred care and shared decision making in all patients with primary hypothyroidism. 
This report summarises the key points in the ETA and ATA guidelines and contains a 
statement on the management of primary hypothyroidism written by the BTA and 
endorsed by the ACB, BTF, RCP and SFE based on the current evidence and 
international guidelines. 
Methods 
The current statement serves to update the previous 2006 RCP joint position 
statement on the diagnosis and management of primary hypothyroidism. We have 
focused on patients with primary hypothyroidism and have not addressed in detail 
the care of subgroups such as pregnant women, patients treated for thyroid cancer, 
or secondary hypothyroidism. Excellent guidelines for the management of these 
other conditions are available elsewhere. The statement is intended to provide 
concise guidance for primary care practitioners, hospital physicians, clinical 
biochemists, and endocrinologists involved in caring for patients with hypothyroidism. 
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A plain English summary of the guidelines will be made available for patients and 
interested members of the public on the websites of the BTA and BTF. 
The statement has been developed following consultation within the BTA and with 
relevant stakeholder groups. All authors are members of the BTA executive 
committee with expertise in thyroid disease management and research. An initial 
face to face meeting was held in December 2014 by committee members, during 
which the scope and remit of the proposed position statement was decided. 
Following this, individual reviewers undertook a primary review that addressed key 
clinical questions relating to the diagnosis, indications, monitoring, therapeutic 
choice, and treatment targets in the management of hypothyroidism. The primary 
reviewers examined the recent hypothyroidism guidelines of the ATA and ETA 
including original research informing these guidelines that was considered relevant 
to the remit of the current position statement. Furthermore a systematic search of 
PubMed was undertaken and additional references were sourced through references 
of individual articles. An initial draft was sent out to consultation by e-mail to 
executive and senior members of the BTA who revised the original draft. Consensus 
on recommendations was reached through discussions. Wider consultations were 
then held with representatives of the SFE, ACB, and RCP, as well as with the BTF, 
the patient support charity for thyroid disorders. The document was finalised 
following feedback from each of these bodies and agreement from all authors was 
reached on the final statement. No external funding was received, either by the BTA 
or by individual members, for the development of this statement, and all conflicts of 
interests are declared. 
In addition to the statement we have summarised the relevant recommendations 
from the ATA and ETA guidelines relating to the diagnosis and management of 
Page 6 of 31Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Management of primary hypothyroidism  
7 | P a g e  
 
primary hypothyroidism. These recommendations are grouped into themes each 
addressing a specific clinical question. The strength of the recommendations and the 
quality of the evidence supporting these recommendations are included as judged by 
the authors of the original guidelines. Recommendations made in the BTA statement 
are also rated as strong (1) or weak recommendations (2) and the quality of 
evidence rated as high (+++), moderate (++0), low (+00), or insufficient (000) 
according to the GRADE system classification for clinical practice recommendations 
[30, 31]. 
Summary of ETA and ATA guidelines  
The key recommendations are summarised in Tables 1-10 and each Table 
addresses a relevant question reviewed in either or both guidelines.  
1. L-T4 is the treatment of choice in hypothyroidism. The goal of therapy is to 
restore physical and psychological well-being and normalise serum TSH (Table 
1). 
2. The adequacy of therapy should be determined both by clinical and biochemical 
assessment and under-treatment and over-treatment should be avoided due to 
their detrimental health effects (Table 2). 
3. There is insufficient evidence to recommend monitoring serum T3 as a 
therapeutic target in hypothyroidism (Table 3). 
4. A proportion of patients on L-T4 therapy have persistent symptoms despite 
normal serum TSH levels. Such symptoms should be acknowledged and 
alternative aetiologies sought (Table 4). 
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5. There is insufficient evidence that combination therapy with L-T4 and L-T3 
therapy is superior to L-T4 monotherapy (Table 5). 
6. L-T4/L-T3 therapy may be considered as an “experimental approach” in 
compliant LT4-treated hypothyroid patients who have persistent complaints 
despite reference range serum TSH values, provided they have received 
adequate chronic disease support and associated autoimmune diseases have 
been ruled out (ETA) (Table 5-6). There is currently insufficient evidence to 
support the routine use of such a trial of L-T4 and L-T3 outside a “formal clinical 
trial or N of 1 trial” (ATA) (Table 5). 
7. Thyroid hormone therapy is not recommended in euthyroid individuals with (i) 
suggestive symptoms of hypothyroidism, (ii) obesity, (iii) depression or (iv) 
urticaria (Table 7). 
8. The routine use of thyroid extracts, L-T3 monotherapy, compounded thyroid 
hormones, iodine containing preparations, dietary supplementation, 
nutraceuticals and over the counter preparations are not recommended in the 
management of hypothyroidism (Table 8).  
9. Genetic characterisation for deiodinase gene polymorphisms is not 
recommended as a guide to the use of combination L-T3 and L-T4 therapy in 
hypothyroidism (Table 9). 
10. Clinicians treating patients with hypothyroidism have an ethical obligation to avoid 
potential harmful therapies without proven benefits. The balance of clinical 
evidence regarding the efficacy of monotherapy versus combination therapy calls 
for further well designed randomised controlled trials (Table 10). 
Page 8 of 31Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Management of primary hypothyroidism  
9 | P a g e  
 
Commentary 
The ETA and ATA guidelines differ in scope although the key recommendations on 
the diagnosis and management of hypothyroidism are comparable. The ATA 
guidelines comprehensively address the management of hypothyroidism and include 
sections on in-hospital management, secondary hypothyroidism, the use of thyroid 
hormone analogues, and ethical considerations for clinicians and researchers. The 
ETA document on the other hand focuses specifically on the use of combination 
therapy and includes carefully considered suggestions for prescribing L-T3 in 
practice.  
Both guidelines strongly recommend that L-T4 remain the therapy of choice in 
hypothyroidism and do not support the routine use of L-T4/L-T3 combination therapy 
due to insufficient evidence from controlled trials, lack of long-term L-T3 safety data, 
and unavailability of L-T3 formulations that mirror natural physiology.  
A key feature of both guidelines is the acknowledgement of the subset of L-T4 
treated patients who suffer persistent symptoms despite adequate biochemical 
thyroid status. However while both guidelines agree that a trial of L-T3 may 
occasionally be indicated in such patients there are significant differences between 
the guidelines in the implementation of such a trial.  
The ETA would consider a carefully monitored experimental trial of L-T3 if symptoms 
persist after co-morbid conditions have been excluded. Such a trial should be 
conducted under specialist supervision, be reassessed after a period of three 
months and preferably include objective evaluations of response with standardised 
quality of life tools.  
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The ATA go further by insisting that any such trial must be rigorously implemented, 
either as part of a clinical trial, or N of 1 trial, with formal ethical and governance 
approvals. In addition the ATA highlight the ethical and legal obligations inherent on 
clinicians managing hypothyroidism including the responsibility to avoid potentially 
harmful therapies without proven advantage over existing therapies. The authors 
further assert that the balance of clinical evidence on the benefits of combination 
therapy over L-T4 monotherapy would demand that further randomised controlled 
trials are indicated.   
The 2011 RCP statement concluded that L-T3 “should be reserved for use by 
accredited endocrinologists in individual patients” but did not specifically address 
management strategies for L-T4 treated patients with persistent symptoms after non-
thyroid causes are excluded. Thus, the current ETA and ATA guidelines can be seen 
as an addition rather than a departure from this position. 
Statement 
Based on the current literature and following review of the published positions of the 
ETA and ATA, and in line with the best principles of good medical practice, the BTA, 
ACB, BTF, RCP and SFE have agreed the following statement: 
1. It is important that high quality, unbiased, evidence based information about 
hypothyroidism is made available to patients and the public. We recognise the 
need to engage with patients and promote more research in hypothyroidism.  
2. The diagnosis of primary hypothyroidism is based on clinical features of 
hypothyroidism supported by biochemical evidence i.e. elevated serum TSH 
together with low free T4 (overt hypothyroidism) or normal free T4 (subclinical 
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hypothyroidism). Primary hypothyroidism should not be diagnosed in individuals 
with normal serum TSH who otherwise have intact pituitary function (1/++0). 
3. The evidence in favour of narrowing the serum TSH reference range is not 
convincing and cannot justify the large increase in the number of healthy people 
that would require investigation (1/++0). 
4. A significant proportion of healthy subjects in the community have asymptomatic 
chronic autoimmune thyroiditis and a significant proportion have subclinical 
hypothyroidism. Spontaneous recovery has been described in subjects with 
subclinical hypothyroidism. It is more likely in those with negative anti-thyroid 
antibodies and serum TSH levels less than 10 mU/L, and within the first two 
years after diagnosis. The higher the serum TSH value, the greater the likelihood 
of development of overt hypothyroidism in subjects with chronic autoimmune 
thyroiditis. 
5. Synthetic L-T4 remains the treatment of choice in hypothyroidism with the aim of 
therapy being to restore physical and psychological well-being while maintaining 
normal laboratory reference range serum TSH lev ls (1/++0). After initiation of 
therapy TSH should be monitored 6-8 weekly and the dose of L-T4 should be 
adjusted until a stable TSH is achieved, after which TSH can be checked 4-6 
monthly, and then annually (1/+00). 
6. It is acknowledged that a proportion of individuals on L-T4 are not satisfied with 
therapy and have persistent symptoms despite a normal serum TSH. Such 
symptoms should be given due consideration and patients should be thoroughly 
evaluated for other potentially modifiable conditions (Box 1). In some cases a 
retrospective review of the original diagnosis of hypothyroidism may be 
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necessary. Symptom and lifestyle management support should be provided and 
further dose adjustments may be required (1/+00). 
7. Although fine tuning of serum TSH levels within the reference range may be 
indicated for individual patients, deliberate serum TSH suppression with high 
dose thyroid hormone replacement therapy (serum TSH <0.1 mU/L) should be 
avoided where possible as this carries a risk of adverse effects such as cardiac 
rhythm disorders including atrial fibrillation, strokes, osteoporosis and fracture 
(1/++0). As an exception, patients with a history of thyroid cancer may require 
deliberate suppression of serum TSH if there is a significant risk of recurrence. 
8. For the vast majority of patients on L-T4, brand or named supplier prescribing is 
not considered necessary (2/+00). The Medicines and Healthcare Products 
Regulatory Agency (MHRA) have recently made recommendations to ensure the 
quality and consistency of L-T4 tablets that are on the UK market. Rarely patients 
may require a specific brand of L-T4 to be prescribed due to intolerance of 
generic preparations. 
9. Serum T3 should not be used as a therapeutic target in the management of 
hypothyroidism as the value of this approach is unproven (1/+00). 
10. L-T4/L-T3 combination therapy in patients with hypothyroidism should not be 
used routinely, as there is insufficient evidence to show that combination therapy 
is superior to L-T4 monotherapy (1/++0). 
11. Clinicians have an ethical responsibility to adhere to the highest professional 
standards of good medical practice rooted in sound evidence. This includes not 
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prescribing potentially harmful therapies without proven advantages over existing 
treatments. 
12. If a decision is made to embark on a trial of L-T4/L-T3 combination therapy in 
patients who have unambiguously not benefited from L-T4 then this should be 
reached following an open and balanced discussion of the uncertain benefits, 
likely risks of over-replacement and lack of long-term safety data. Such patients 
should be supervised by accredited endocrinologists with documentation of 
agreement after fully informed and understood discussion of the risks and 
potential adverse consequences. Many clinicians may not agree that a trial of L-
T4/L-T3 combination therapy is warranted in these circumstances and their 
clinical judgement must be recognised as being valid given the current 
understanding of the science and evidence of the treatments (2/+00). 
13. The serum TSH reference range in pregnancy is 0.4-2.5 mU/L in the first 
trimester and 0.4-3.0 mU/L in the second and third trimesters or should be based 
on the trimester specific reference range for the population if available. These 
reference ranges should be achieved where possible with appropriate doses of L-
T4 pre-conception and most importantly in the first trimester (1/++0). L-T4/L-T3 
combination therapy is not recommended in pregnancy (1/+00). 
14. There is no convincing evidence to support routine use of thyroid extracts, L-T3 
monotherapy, compounded thyroid hormones, iodine containing preparations, 
dietary supplementation and over the counter preparations in the management of 
hypothyroidism (1/+00).  
  
Page 13 of 31 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Management of primary hypothyroidism  
14 | P a g e  
 
Conclusions 
This updated position statement reflects current best practice in the management of 
primary hypothyroidism. Levothyroxine therapy offers a safe, rational, and simplified 
approach to the correction of hypothyroidism, and for the vast majority of patients, 
treatment results in improved physical and psychological well-being. However the 
management of patients with a sub-optimal clinical response remains challenging. 
The benefits of combination therapy with LT-4 and LT-3 are still unproven and the 
potential for harm exists with unregulated use of unapproved therapies. Thus, future 
RCTs will be of value, especially on the use of combination therapy in patients with 
specified genetic or clinical characteristics. Strategies to improve medication 
adherence, optimise drug delivery, and standardise thyroid hormone formulations will 
ultimately improve patient outcomes. The BTA hopes that this position statement 
along with other recently published scientific guidelines would support clinicians in 
implementing evidence based strategies in the management of hypothyroidism.  
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L-T4  Levothyroxine, 
FT4,  Free thyroxine 
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L-T3 Liothyronine 
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STRENGTH OF RECOMMENDATIONS  
1 Strong recommendation 
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TABLE 1: CHOICE OF THERAPY AND THERAPEUTIC TARGETS 
Question Guideline Recommendation  
Strength/ 
Evidence 
Why is L-T4 monotherapy 
considered to be the standard of 
care for hypothyroidism? 
ATA L-T4 is recommended as the preparation of choice for the treatment of 
hypothyroidism due to its efficacy in resolving the symptoms of hypothyroidism, 
long-term experience of its benefits, favourable side effect profile, ease of 
administration, good intestinal absorption, long serum half-life and low cost. 
1/++0 
What are the clinical and 
biochemical goals for L-T4 
replacement in primary 
hypothyroidism? 
ATA L-T4 replacement therapy has three main goals. These are (i) to provide 
resolution of patients’ symptoms and hypothyroid signs, including biological 
and physiologic markers of hypothyroidism, (ii) to achieve normalization of 
serum TSH with improvement in thyroid hormone concentrations, and (iii) to 
avoid overtreatment (iatrogenic thyrotoxicosis) especially in the elderly. 
1/++0 
Are clinical parameters such as 
cold sensitivity and dry skin useful 
by themselves for assessing 
adequacy of L-T4 replacement in 
primary hypothyroidism? 
ATA Although it may be helpful to follow changes in clinical symptoms longitudinally 
in patients treated for hypothyroidism, symptoms alone lack sensitivity and 
specificity and therefore are not recommended for judging adequacy of 
replacement in the absence of biochemical assessment. Therefore, symptoms 
should be followed, but considered in the context of serum TSH values, 
relevant co-morbidities, and other potential causes 
1/+00 
Are tissue markers of thyroid 
hormone action helpful in 
determining the adequacy of L-T4 
replacement in primary 
hypothyroidism? 
ATA Tissue biomarkers of thyroid hormone action are not recommended for routine 
clinical use, outside of the research setting, since these parameters are not 
sensitive, specific, readily available, or standardized. 
 
2/+00 
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TABLE 2: EFFECTS OF INADEQUATE OR EXCESS L-T4 THERAPY 
Question Guideline Recommendation  
Strength/ 
Evidence 
What are the potential deleterious 
effects of excessive L-T4? 
 
ATA The deleterious health effects of iatrogenic thyrotoxicosis include atrial 
fibrillation and osteoporosis. Because of these effects we recommend avoiding 
thyroid hormone excess and subnormal serum TSH values, particularly serum 
TSH values below 0.1 mU/L, especially in older persons and post-menopausal 
women. 
1/++0 
 
What are the potential deleterious 
effects of inadequate L-T4? 
 
ATA The adverse effects of thyroid hormone deficiency include detrimental effects 
on the serum lipid profile and progression of cardiovascular disease. We 
recommend that patients with overt hypothyroidism be treated with doses of 
L-T4 that are adequate to normalize serum TSH, in order to reduce to eliminate 
these undesirable effects. 
1/++0 
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TABLE 3: ROLE OF SERUM FREE T3 IN THE MANAGEMENT OF HYPOTHYROIDISM 
Question Guideline Recommendation  Strength/ Evidence 
Are variations in serum T3 
concentrations within the reference 
range of physiologic or clinical 
significance? In addition, are mildly 
low serum T3 concentrations of 
clinical significance? 
ATA The significance of perturbations in serum T3 concentrations within the 
reference range, or of mildly low serum T3, is unknown. 
 
SS 
Does L-T4 therapy that returns the 
serum TSH levels of hypothyroid 
patients to the reference range also 
result in normalization of their 
serum T3 levels? 
ATA Patients with hypothyroidism treated with L-T4 to achieve normal serum TSH 
values may have serum T3 concentrations that are at the lower end of the 
reference range, or even below the reference range. The clinical significance of 
this is unknown. 
 
SS 
Should L-T4 therapy for 
hypothyroidism, particularly in 
specific subgroups such as those 
with obesity, depression, 
dyslipidaemia, or who are 
athyreotic, be targeted to achieve 
high-normal serum  free T3 levels 
or low-normal serum TSH levels? 
ATA There is insufficient evidence of benefit to recommend that treatment with L-T4 
be targeted to achieve low-normal serum TSH values or high normal serum T3 
values in patients with hypothyroidism, including those who are overweight, or 
those who have depression, dyslipidaemia, or who are athyreotic. 
 
1/++0 
Is there evidence of discordance 
between the thyroid hormone 
status of different tissues and the 
serum TSH concentration? 
ATA There are specific instances in which there appears to be discordance between 
the thyroid status of the pituitary gland, as reflected by the serum TSH, and the 
thyroid status of other tissues as indicated by various biomarkers. The clinical 
significance of this is not known. 
SS 
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TABLE 4: PATIENT SATISFACTION WITH L-T4 THERAPY  
Question Guideline Recommendation  
Strength/ 
Evidence 
Is there an unmet need in LT4-
treated patients with 
hypothyroidism? 
ETA In LT4-treated hypothyroid patients with normal serum TSH values, 
psychological distress, impaired wellbeing and cognitive disturbances occur 
more often than in controls. 
1/+00 
Data suggest that 5–10% of L-T4 treated hypothyroid patients with normal 
serum TSH have persistent symptoms which can be related to the disease and 
L-T4 therapy. 
2/+00 
Is there a biologic rationale for 
persistent complaints in L-T4 
treated hypothyroid patients? 
 
 
ETA Suggested explanations for persistent symptoms in L-T4 treated hypothyroid 
patients despite normalisation of serum TSH, include: Awareness of a chronic 
disease, presence of associated autoimmune diseases, thyroid autoimmunity 
per se (independent of thyroid function), and inadequacy of L-T4 treatment to 
restore physiological T4 and T3 concentrations in serum and tissues. 
2/+00 
What approach should be taken in 
patients treated for hypothyroidism 
who have normal serum TSH 
values but still have unresolved 
symptoms? 
 
ATA A minority of patients with hypothyroidism, but normal serum TSH values, may 
perceive a suboptimal health status of unclear aetiology. Acknowledgement of 
the patients’ symptoms and evaluation for alternative causes is recommended 
in such cases. Future research into whether there are sub-groups of the 
population being treated for hypothyroidism who might benefit from 
combination therapy should be encouraged. 
2/+00 
 
What tools may be useful in the 
clinical or research setting, to 
measure the impact of L-T4 
replacement for primary 
hypothyroidism on patients’ 
physical or psychological well-
being, treatment satisfaction, or 
treatment preferences? 
ATA Of the established instruments used to measure hypothyroid symptoms, data 
are lacking regarding their sensitivity and specificity in the “everyday” clinical 
setting to recommend their routine clinical use. Further studies are needed to 
determine if and how to combine general psychological screening instruments, 
hypothyroidism-specific tools, and laboratory assessment of thyroid function to 
measure the impact of L-T4 replacement therapy on psychological well-being, 
treatment satisfaction, and preference in clinical practice. A combination of 
general instruments, combined with hypothyroidism-specific tools, may be the 
most effective way to examine psychological well-being in the L-T4 treated 
population in the research setting. 
1/++0 
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TABLE 5: COMBINATION THERAPY WITH L-T4 AND L-T3  
Question Guideline Recommendation  
Strength/ 
Evidence 
Is combination therapy with L-T4 
and L-T3 superior to L-T4 
monotherapy in the management 
of hypothyroidism? 
ETA Insufficient evidence that L-T4 + L-T3 combination therapy is superior to L-T4 
monotherapy.   
1/++0 
 
L-T4 monotherapy remains the standard treatment of hypothyroidism. 1/+++ 
ATA There is no consistently strong evidence of superiority of combination therapy 
over monotherapy with L-T4. Therefore, we recommend against the routine 
use of combination treatment with L-T4 and L-T3 as a form of thyroid 
replacement therapy in patients with primary hypothyroidism, based on 
conflicting results of benefits from randomised controlled trials comparing this 
therapy to L-T4 therapy alone and a paucity of long-term outcome data. 
2/++0 
Is there a place for combination 
therapy with L-T4 and L-T3 in 
patients who have persistent 
symptoms despite serum TSH 
values within the reference range? 
ETA Consider L-T4 and L-T3 as an experimental approach in compliant L-T4 
treated hypothyroid patients who have persistent complaints despite serum 
TSH values within the reference range, provided they have previously been 
given support to deal with the chronic nature of their disease and associated 
autoimmune diseases have been ruled out. 
2/+00  
L-T4 and L-T3 are not recommended in pregnancy and in patients with cardiac 
arrhythmias. 
2/+00 
Discontinue L-T4 and L-T3 if no improvement after three months. 2/++0 
ATA For patients with primary hypothyroidism who feel unwell on L-T4 therapy 
alone (in the absence of an allergy to L-T4 constituents or an abnormal serum 
TSH), there is currently insufficient evidence to support the routine use of a trial 
of a combination of L-T4 and L-T3 therapy outside a formal clinical trial or N of 
1 trial, due to uncertainty in long-term risk benefit ratio of the treatment and 
uncertainty as to the optimal definition of a successful trial to guide clinical 
decision-making. 
000 
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TABLE 6: DOSE, ADMINISTRATION AND MONITORING OF L-T3 THERAPY 
Question Guideline Recommendation  
Strength/ 
Evidence 
What is the appropriate dose of L-
T4 and L-T3? 
ETA Start L-T4+L-T3 at L-T4/L-T3 dose ratio between 13:1 and 20:1 by weight. 2/+00  
L-T4 can be given once daily, the daily L-T3 dose should be divided (if 
possible) in two doses, one before breakfast and the largest one before bed. 
2/+00 
Which preparations can be used in 
L-T4 and L-T3 combination therapy 
and how should their use be 
monitored? 
ETA Available LT4+LT3 combination preparations contain a LT4/LT3 dose ratio 
lower than 13:1, so it is recommended to use separate LT4 and LT3 tablets. 
1/+00 
L-T4+L-T3 should be monitored by thyroid function tests in blood samples 
taken before the morning dose, aiming at normal serum TSH, free T4 (FT4), 
free T3 (FT3), and FT4/FT3 ratio. 
1/++0  
If dose adjustment of L-T4+L-T3 combination therapy is necessary to achieve a 
normal serum TSH, free T4, free T3, and FT4/FT3 ratio, the dose of one 
component, preferably L-T3, should be changed,.  
2/+00  
L-T4 and L-T3 therapy should be supervised by accredited internists or 
endocrinologists 
2/++0 
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TABLE 7: USE OF THYROID HORMONE THERAPY IN EUTHYROID INDIVIDUALS 
Question Guideline Recommendation  
Strength/ 
Evidence 
Is there a role for the use of L-T4 to 
treat biochemically euthyroid 
patients with symptoms that 
overlap with those of 
hypothyroidism? 
ATA Strongly recommend against the use of L-T4 treatment in patients who have 
nonspecific symptoms and normal biochemical indices of thyroid function, as 
no role exists for use of L-T4 in this situation.  
 
1/+++ 
Is there a role for the use of L-T4 or 
L-T3 to treat euthyroid patients with 
depression? 
ATA Recommend against the routine use of L-T4 for the treatment of euthyroid 
individuals with depression, due to a paucity of controlled data examining 
treatment efficacy in this setting. 
2/+00 
Although some uncontrolled and non-randomised data exist concerning 
successful use of L-T3 in euthyroid patients with depression, larger, 
prospective randomised placebo controlled studies are needed to more 
completely define the potential role of L-T3 in this condition, balancing the risks 
and benefits of therapy to measurable clinical outcomes. 
2/+00 
Is there a role for the use of L-T4 or 
L-T3 to treat euthyroid patients with 
obesity?  
ATA Recommend against the treatment of obesity with L-T4 in euthyroid individuals, 
due to a lack of treatment efficacy for this condition. 
1/++0 
Recommend against the treatment of obesity with synthetic L-T3 due to a lack 
of controlled data proving treatment efficacy for this indication. 
1/+00 
Is there a role for the use of L-T4 to 
treat euthyroid patients with 
urticaria? 
ATA Recommend against the treatment of urticaria with L-T4 in euthyroid 
individuals, due to a lack of treatment efficacy for this condition 
1/++0 
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TABLE 8: ROLE OF OTHER THERAPIES IN HYPOTHYROIDISM 
Question Guideline Recommendation  
Strength/ 
Evidence 
Is treatment with thyroid extracts 
superior to treatment with L-T4 
alone? 
ATA Although there is preliminary evidence from a short-duration study that some 
patients may prefer treatment with extracts, high quality controlled long-term 
outcome data are lacking to document superiority of this treatment compared 
to L-T4 therapy. Furthermore, there are potential safety concerns related to the 
use of thyroid extracts, such as the presence of supraphysiological serum T3 
levels and a paucity of long-term safety outcome data. 
1/++0 
Are there data regarding therapy 
with L-T3 alone, either as standard 
L-T3 or as sustained release L-T3, 
that support the use of L-T3 
therapy alone for the treatment of 
hypothyroidism? 
ATA Although short-term outcome data in hypothyroid patients suggest that thrice 
daily synthetic L-T3 may be associated with beneficial effects on parameters 
such as weight and lipids, longer-term controlled clinical trials using a longer 
acting form of L-T3 are needed, before considering the endorsement of 
synthetic L-T3 therapy for routine clinical use. 
1/++0 
What is the recommendation 
regarding therapy with 
compounded thyroid hormones 
(either L-T4 or L-T3) for treatment 
of hypothyroidism based on current 
evidence? 
ATA Recommend against the routine use of compounded thyroid hormones due to 
concerns about safety and potency and due to the lack of data proving 
superiority to standard thyroid hormone preparations. However, in the case of 
suspected allergy to an excipient of standard thyroid hormone preparations 
that cannot be avoided with a change in brand or dose formulation, including a 
trial of L-T4 gel capsules, it may be reasonable to consider use of compounded 
products, although a controlled study of this approach has not been published.  
1/+00 
 
Is there a role for the use of dietary 
supplementation, nutraceuticals, 
and over the-counter products in 
either hypothyroid or euthyroid 
individuals? 
ATA Recommend against the use of dietary supplements, nutraceuticals, or other 
over the counter products either in euthyroid individuals or as a means of 
treating hypothyroidism. Particularly caution against the use of pharmacologic 
doses of iodine because of the risk of thyrotoxicosis and hypothyroidism in 
those with intact thyroid glands susceptible to becoming further dysregulated 
because of underlying thyroid pathology. 
1/+00 
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TABLE 9: IMPACT OF GENETIC POLYMORPHISMS ON THE RESPONSE TO THERAPY 
Question Guideline Recommendation  
Strength/ 
Evidence 
Could it be that trials comparing L-
T4 and L-T3 combination therapy 
and L-T4 monotherapy have not 
targeted the right population? 
 
ETA Limited data suggest that psychological well-being and preference for L-T4 and 
L-T3 combination therapy may be influenced by polymorphisms in thyroid 
hormone pathway genes, specifically in thyroid hormone transporters and 
deiodinases. 
2/+00 
Should genetic characterization 
according to type 2 deiodinase 
gene polymorphism status be used 
to guide the use of combination 
synthetic L-T3 and L-T4 therapy in 
hypothyroidism, in order to 
optimise biochemical and clinical 
outcomes? 
ATA Currently, genetic testing is not recommended as a guide to selecting therapy 
for 3 reasons. i) Although there are data suggesting that specific 
polymorphisms of the type 2 deiodinase gene might be associated with 
therapeutic response to combination synthetic L-T3 and L-T4 therapy, 
controlled confirmatory studies are needed. ii) Currently genetic testing for 
these specific deiodinase polymorphisms is only available in the research 
setting. iii) The small effect of the type 2 deiodinase gene variants identified so 
far that do affect thyroid hormone concentrations suggests that other factors 
(e.g. yet unidentified genetic variants) may play a far greater role in 
determining an individual patient’s thyroid hormone concentrations. 
1/++0 
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TABLE 10: ETHICAL CONSIDERATIONS  
Question Guideline Recommendation  
Strength/ 
Evidence 
What are the ethical obligations of 
clinicians in treating 
hypothyroidism? 
 
ATA Clinical ethical principles in L-T4 treatment for hypothyroidism revolve around 
two core ethical principles in medicine: the principles of beneficence and non-
maleficence, which guide the risk/benefit analysis in clinical practice, and 
protect clinicians from deviating from practice to satisfy inappropriate patient 
demands. Additional ethical obligations revolve around the professional virtues 
of competence and intellectual honesty. 
Ungraded 
What are the research ethics 
issues involved in evaluating or 
designing clinical trials for the 
treatment of hypothyroidism? 
ATA There should be recognition that there are not enough data to resolve clinical 
disagreement amongst thyroid experts (called “clinical equipoise”) regarding 
treatment for hypothyroidism. Clinical equipoise is disturbed only by the results 
of well-designed randomised controlled trials that have the statistical power to 
settle the question of efficacy between monotherapy and combination therapy, 
or other forms of therapy. 
Ungraded 
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Box 1: Some possible causes of persistent symptoms in euthyroid patients on L-T4 
Endocrine/autoimmune  
 Diabetes Mellitus 
 Adrenal insufficiency 
 Hypopituitarism  
 Coeliac disease 
 Pernicious anaemia  
Haematological 
 Anaemia  
 Multiple myeloma  
End-organ damage 
 Chronic kidney disease 
 Chronic liver disease 
 Congestive cardiac failure 
Nutritional  
 Vitamin B12 deficiency 
 Folate deficiency 
 Vitamin D deficiency  
 Iron deficiency 
Metabolic  
 Obesity  
 Hypercalcaemia 
 Electrolyte imbalance 
Drugs 
 Beta-blockers 
 Statins 
 Opiates 
Lifestyle  
 Stressful life events 
 Poor sleep pattern 
 Work related exhaustion  
 Alcohol excess 
Others 
 Obstructive sleep apnoea 
 Viral and post viral syndromes 
 Chronic fatigue syndrome  
 Carbon monoxide poisoning 
 Depression and anxiety  
 Polymyalgia rheumatica 
 Fibromyalgia 
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